PATENT CLAIM ANALYSIS

Application Number: 15895655
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-11
Patent Classification: ["424", "134100"]

Abstract:
The present disclosure provides a method for enhancing the anti-tumor efficacy of an Fc fusion protein which binds specifically to a target, e.g., a co-inhibitory or co-stimulatory receptor of ligand, on a T cell in a subject afflicted with a cancer or a disease caused by an infectious agent and alters the activity of the immunomodulatory target, thereby potentiating an endogenous immune response against cells of the cancer or the infectious agent, wherein the method comprises selecting, designing or modifying the Fc region of the Fc fusion protein so as to enhance the binding of said Fc region to an activating Fc receptor (FcR). The disclosure also provides an Fc fusion protein produced by said method and its use in treating a subject afflicted with a cancer or a disease caused by an infectious agent.

Claim (Index 4):
The antibody of  claim 2  wherein the antibody is nonfucosylated.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 88.0
- Lexical Diversity: 1.9863
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15071489', '15369290', '14949424', '15646558', '14732082']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8078074630575364
- 35 USC 102 Novelty (BERT): 0.5726873738304057
- Combined Prediction Score: 0.7842954541348234
- Mean Citation Score: 456.7607
- Max Citation Score: 552.5124
- Similarity Product: 349.8103393064261

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test